PDF-HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include

Reference ID 3406989FULL PRESCRIBING INFORMATION INDICATIONS AND USAGE luliconazole Cream 1 is indicated for the topical treatment of interdigital tinea pedis tinea cruris and tinea corporis caused b. See full prescribing information for Ferric Citrate Ferric Citrate ablet containing 210 mg of ferric iron equivalent to 1 g ferric citrate for ral se Initial U Approval 2014 INDICATIONS AND USAGE Ferric Citrate s a phosphate binder indicated for See full prescribing information for LATISSE LATISSE bimatoprost ophthalmic solution 003 Initial US Approval 2001 INDICATIONS AND USAGE LATISSE is a prostaglandin analog indicated to treat hypotrichosis of the eyelashes by increasing their growth --------------------------RECENT MAJOR CHANGES---------------------------- Boxed Warning 04/15 Indications and Usage (1.1) 04/15 Dosage and Administration (2.1, 2.2) 04/15 Warnings a FULL PRESCRIBING INFORMATION INDICATIONS AND USAGE SOMA is indicated for the relief of discomfort associated with acute, painful itions in adults. SOMA should only be used for short periods (up to two NDA 22-288/S-003 Reference ID: 3151309 NDA 22-288/S-003 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE BEPREVE (bepotastine besilate ophthalmic solution) 1.5% is a histamine H receptor antagoni Dr L . Varadhan. C2017 Meeting – Doctor as Practitioner. 1. st. June 2016. Agenda. Current teaching offered year-wise in hospitals. What is expected at the end of academic years. Broad overview of changes needed. 5.1Hypersensitivity5.2Exogenous Ochronosis5.3Effects on Endocrine System5.4Cutaneous ReactionsADVERSE REACTIONSUSE IN SPECIFIC POPULATIONS8.1Pregnancy8.3NursingMothers8.4Pediatric Use8.5Geriatric Use1 Limitation of Use Should only be used for acute treatment periods up to two or three weeks (1)------------------------DOSAGE AND ADMINISTRATION------------------- DESCRIPTIONCLINCIAL PHARMACOLOGY12.1 FULL PRESCRIBING INFORMATION CONTENTS INDICATIONS AND USAGEDOSAGE AND ADMINISTRATIONDOSAGE FORMS AND STRENGTHSCONTRAINDICATIONSWARNINGS AND PRECAUTIONS5152Nephrotoxicity53Neuromuscular Disorders54Bron Dermatologic ToxicityTemporarily interruptPOTELIGEO for moderate or severe skin rashes Permanently discontinue POTELIGEO for lifethreatening rash 51InfusionReactionsTemporarily interruptfor any infusi BALVERSA2FULL PRESCRIBING INFORMATION INDICATIONS AND USAGEBALVERSA is indicated for the treatment of adult patients with locally advanced or chemotherapy including within 12 months of neoadjuvant treatment and adjust dosing as needed 22 51 constipation nausea and vomiting as needed 22 52 Peripheral Neuropathy Monitor patients for symptoms of peripheral neuropathy and adjust dosing as needed 2 Limitations of Use: Due to the possible association between malignancy and calcitoninsalmon use, the need for continued therapy should be reevaluated on a . -------------------------------DRUG INTER EXTRAVASATION AND TISSUE NECROSIS, and SEVERE MYELOSUPPRESSION See full prescribing information for complete boxed warning. Cardiomyopathy: Myocardial damage can occur with doxorubicin HCl with inc